Trial Profile
Phase Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate the Safety and Activity of the Combination of Crizotinib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Mar 2022
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- 09 Mar 2022 Status changed from active, no longer recruiting to completed.
- 07 Jan 2021 Planned End Date changed from 1 Nov 2020 to 1 Aug 2021.
- 22 Jul 2020 Planned End Date changed from 1 May 2020 to 1 Nov 2020.